2022-23 Academic Calendar (PDF)
« All Events
Please join us for our Research Seminar Series Speaker, Leticia Reyes-Regis, Senior Principal Scientist, Pall Corporation.
In recent years, there has been a strong interest to use AAV particles as viral vectors as evidenced by the growing number of clinical successes and agency approvals for AAV therapeutics. AAV-based gene therapies offer a better quality of life to patients with life-debilitating conditions and serve as gene augmentation therapy for missing or mutated genes that would normally produce critical proteins in the human body. Much emphasis has been placed on clinical development of AAV-based gene therapies. Thus, clinical development of AAV vectors has outpaced manufacturing development. A scalable and reproducible manufacturing platform to produce AAV is necessary to ensure the robustness of the entire process. As the field of AAV-mediated gene therapy progresses, the need for scalable methods of AAV production becomes of growing importance to the translation of successful preclinical investigations to human clinical trials and therapy commercialization. This presentation shows the optimization of each unit step in the downstream processing of AAV, from clarification to the final sterilization-grade filtration. The DSP also includes the enrichment of the full AAV capsid and the optimization of this step using the Mustang Q membrane chromatography.
Date: Friday, December 2, 2022
Time: 12:00 – 1:00 p.m.
Location: 121 Bldg. – 1111 Classroom and Via Zoom (See Outlook invite for Zoom Link)
Celebrating 25 years of innovation! 25.kgi.edu.